%0 Journal Article %T Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk? %A Latif, Hira %A Liu, Stephen V. %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk? %K %X Immunotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) and offers the potential for meaningful, durable responses in a subset of patients. Ongoing efforts are focused on extending these benefits to more patients. %U https://atm.amegroups.org/article/view/24995 %P S76 %@ 2305-5847